Patents

Description

DERIVAŢI DE BENZAZEPINĂ, PROCEDEU DE PREPARARE, COMPOZIŢIE FARMACEUTICĂ CARE ÎI CUPRINDE ŞI UTILIZAREA ACESTORA

Price not visible for this package

Interest:

Assignment

Publication info:

No.: RO119881

Date: 30.05.2005

Inventor(s):

CALLAHAN JAMES FRANCIS [US]

COUSINS RUSSELL DONOVAN [US]

KEENAN RICHARD MCCULLOCK [US]

KWON CHET [US]

MILLER WILLIAM HENRY [US]

UZINKAS IRENE NIJOLE [US]

Applicant(s):
SMITHKLINE BEECHAM CORP [US]
Classification:
International patent classification (IPC):
A61K31/415; A61K31/44; A61K31/445; A61K31/47; A61K31/4704; A61K31/495; A61K31/52; A61K31/55; A61K31/551; A61K33/243; A61K45/06; A61P19/10; A61P29/00; A61P35/00; A61P43/00; A61P9/00; A61P9/10; C07D223/00; C07D223/16; C07D233/56; C07D233/64; C07D235/18; C07D235/22; C07D243/14; C07D401/00; C07D401/12; C07D401/14; C07D403/12; C07D413/12; C07D417/12; C07D487/00
Cooperative patent classification (CPC):
A61K31/55 (EP); A61K33/243 (EP, US); A61K45/06 (EP); A61P19/10 (EP); A61P29/00 (EP); A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP); C07D223/00 (KR); C07D223/16 (EP); C07D401/12 (EP); C07D403/12 (EP); C07D417/12 (EP); Y02P20/55 (EP); Y02P20/582 (EP); A61K31/55; A61K31/47; A61K2300/00; A61K33/24
Application info:
No.: RO19990000353
Date: 01.10.1997
Priority number(s):
US19960027320P 02.10.1996 ; US19970043776P 11.04.1997 ; WO1997US18001 01.10.1997
Related patents:
AP1463; AR008878; ATE312089; AU4746297; AU733417; BG103299; BG64581; BR9712248; CA2267224; CN1114403; CN1238689; CO4900046; CY2576; CZ113299; CZ299076; DE69734833; DK0957917; DZ2320; EA002419; EA199900356; EP0957917; ES2252775; HK1023730; HU229221; HU9903769; ID19623; IL129243; JP2001501936; JP2010006838; JP4491072; KR100589578; KR20000048816; MA24361; MY137606; NO320194; NO991590; NZ334953; PE10499; PL190859; PL332674; SA98180936; SK285029; SK42599; TR199900737; TW487702; UA60311; UY24735; UY24935; WO9814192
Description:

Invenţia se referă la compuşi care au, ca structură de bază, benzodiazepinil şi care sunt antagonişti ai receptorului de vitronectină şi sunt folositori pentru tratarea osteoporozei, angiogenezei, dezvoltării tumorale şi metastazării, aterosclerozei, restenozei şi inflamaţiei. ŕ

Share this on:
Facebook Twitter/X LinkedIn Whatsapp Email